From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2- (4-hydroxyphenyl)-3-methyl-1H-indol-5-ol
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Routes of
Legal status
Legal status
  • ℞ (Prescription only)
CAS Number 198481-32-2
ATC code G03XC02 (WHO)
PubChem CID 154257
ChemSpider 135921
Chemical data
Formula C30H34N2O3
Molar mass 470.603 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), under development by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. Pfizer are seeking approval for bazedoxifene in the prevention and treatment of postmenopausal osteoporosis[1]. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharamceuticals and Ligand Pharmaceuticals.

It is approved in the European Union, and is currently in the late phases of review by the United States' Food and Drug Administration. When approved, bazedoxifene is to be sold by Pfizer under the tradename Viviant in the US and Conbriza in the EU. Bazedoxifene's combination with conjugated estrogens, Aprela, is currently undergoing Phase III studies.

History of approval

Wyeth received an approvable letter for bazedoxifene in late April 2007. The FDA called for final safety and efficacy data from Phase III studies, and acceptable valuation of manufacturing and testing facilities where problems were found earlier in the year. Wyeth was working with the FDA to resolve these issues, and expected an FDA action date at the end of 2007.

As of July 2009, the FDA have not given approval for the use of bazedoxifene in the US.[2]

The drug was approved in the European Union by the European Medicines Agency on April 27, 2009.[3]



Miller, C.P.; Harris, H.A.; Komm, B.S. (2002). "Bazedoxifene Acetate". Drugs of the Future. 27: 117. doi:10.1358/dof.2002.027.02.637843. 


  1. Biskobing, DM (2007). "Update on bazedoxifene: a novel selective estrogen receptor modulator". Clinical interventions in aging. 2 (3): 299–303. PMC 2685267Freely accessible. PMID 18044180.  edit
  2. "Drugs@FDA - Drug Names Beginning with "B"". Food and Drug Administration. 07 July 2009. Retrieved 2009-07-08.  Check date values in: |date= (help)
  3. "EPARs for authorised medicinal products for human use - Conbriza" (in various). European Medicines Agency. 26 May 2009. Retrieved 2009-07-08.